cyrilzakka/clinical-trials huggingface dataset:
Effects of Convective Therapies in Dialysis Patients

Convective therapies have been proposed for improving chronic dialysis patient outcomes, including intradialytic symptomatic hypotension.

To evaluate the frequency of sessions with intradialytic symptomatic hypotension in different types and doses of convective therapies compared with low-flux hemodialysis (HD), the investigators performed a multicentre, open-label, randomized controlled trial.


Eligibility Criteria:
Inclusion Criteria:

* Dialysis patients aged 18-80 years
* thrice-weekly HD or HDF for at least 6 months
* body weight less or equal to 90 Kg
* stable clinical condition
* written consent

Exclusion Criteria:

* infections
* malignancies
* active systemic diseases
* active hepatitis or cirrhosis
* unstable diabetes
* diuresis higher than 200 ml/24h
* dysfunction of vascular access
* blood flow rate less than 300 ml/min
Investigation of Exercise Training-Induced Myokines and Adipolkines in Humans

The purpose of this study is to find out whether exercise training leads to changes in the blood that are produced by exercised muscles and if these changes produce new hormones that affect the body's regulation of sugar and body weight.


Eligibility Criteria:
Inclusion Criteria:

- Age between 18-35. Body mass index (BMI) must be ≥18.5 and ≤27 kg/m2. HbA1c values ≤5.7%

Exclusion Criteria:

* Age \<18 and \>50
* HbA1c ≥ 5.7%; heart or lung disease
* acute systemic infection accompanied by fever, body aches, or swollen lymph glands
* BMI \> 27 kg/m2
* current dieting or weight loss efforts
* current pregnancy or breastfeeding
* known history of HIV/AIDS; cancer
* biochemical evidence of renal or hepatic dysfunction; renal or liver disease demyelinating diseases such as multiple sclerosis or amyotrophic lateral sclerosis
* recent blood donation
* clinical history of stroke
* hypertension (systolic \> 140 mmHg or diastolic \> 90 mmHg)
* type 1 or 2 diabetes; inability to exercise at 50% of predicted heart rate (HR) reserve at baseline
* Participants taking beta-blockers Participants who screen positive for The American Heart Association's contraindications to exercise testing
Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress

Investigate whether hyperbaric oxygen therapy treatment can become a viable treatment option for COVID-19. If successful, providers will be able to provide future COVID-19 patients with mild-to-moderate respiratory distress hyperbaric oxygen therapy in order to help avoid mechanical ventilation

Using the Monoplace Hyperbaric Oxygen Chambers we will be providing COVID- 19 positive patients with mild-to-moderate distress 100% oxygen at 2.0 ATA for 90 minutes on consecutive days for a total of up to 5 treatments. A comparison will be made using a historical cohort not receiving HBOT. Data will be collected to determine whether or not HBOT is of any benefit to COVID-19 positive patient with mild-to-moderate respiratory distress.

Study Group: Provide 100% oxygen at 2.0 ATA for 90 minutes on consecutive days for a total of up to 5 treatment to COVID-19 patients meeting inclusion criteria Control Group: Any COVID-19 positive patient meeting study inclusion criteria that does not receive HBOT (historical) The control group is further defined as patients who were previously treated for COVID-19 at Morton Hospital that did not receive hyperbaric oxygen therapy. This will require accessing medical records to obtain patient information to establish the historical control data metric.

Study outcome measures:

* Time to normalize 02 requirement (ambient air pulse ox greater than or equal to 92% or ABG w/Pa02 greater than 60mmHG on air)
* Mortality
* Days free of invasive mechanical ventilation

Eligibility Criteria:
Inclusion Criteria:

* Verified COVID-19 infection
* Patient w/02 dependence of less than or equal to 6 liter/min to maintain pulse ox greater than or equal to 92% or arterial gas w/PA02 greater than 60mm HG

Exclusion Criteria:

* Not diagnosed w/COVID-19 infection
* Pregnancy
* DNR or other restrictions in escalation of level of care
* Contraindication for HBO
* Blood pressure parameters which are deemed unstable by clinical team
* Patients who require continuous ECG and/or continuous blood pressure monitoring, and with arterial lines
* Patients requiring rewarming
* Patients requiring any kind of invasive catheter/pressure monitoring
* Patients requiring continuous support of intravenous medication
* Minor subject (less than 18 years old)
* Refusal to participate
* Signs of respiratory decompensation requiring intubation and mechanical ventilation
* 02 dependence greater than or equal to 6L/minute to obtain Sa02 greater than or equal to 92% or ABG w/Pa02 \>60mmHg
Effects of Insoles on Children With Developmental Delays

Using double blind, randomized controlled design to investigate the short-term therapeutic effects of function of customized insoles on children with developmental delays

A total of 52 children with developmental delays will be enrolled. The participants will be randomized into two groups, including study group (with insoles) and control group (without insoles).

The participants in the study group will be evaluated at baseline, that is before the customized insoles are prescribed. All of evaluations, including physical function, balance, and quality of life will be re-evaluated up to 12 weeks after insoles wearing.

The control group will be evaluated at the baseline and up to 12 weeks.

Eligibility Criteria:
Inclusion Criteria:

* developmental delays

Exclusion Criteria:

* age less than 3 years old or older than 10 years old normal development
Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease

The purpose of this project is to study the the efficacy and safety of probiotics implantation through infusion during colonoscopy in the treatment of functional constipation and irritable bowel syndrome. The study is a single-center, prospective, randomized, single-blind, controlled, cohort study. The invesitigators plan to enroll 80 patients with functional constipation and 80 patients with irritable bowel syndrome. The invesitigators will randomize the included study subjects. The experimental group receive basic treatment and a single infusion of probiotics through colonoscopy. The control group receive basic treatment and a single injection of normal saline through colonoscopy. The invesitigators will follow up the patients for 8-12 weeks. The primary endpoint is the efficacy of the single colonoscopic probiotics infusion in functional constipation and irritable bowel syndrome patients. The secondary endpoint is the safety of the single colonoscopic probiotics infusion in functional constipation and irritable bowel syndrome patients. Other exploratory objectives include the alterations in clinical indicators, fecal microbiota, and intestinal microbiota metabolites in feces and serum.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing for colonoscopy
* Meet Rome IV diagnostic criteria for functional constipation or irritable bowel syndrome
* Voluntarily participate in this clinical study and sign the informed consent.

Exclusion Criteria:

* Use of probiotics or antibiotics within the past 4 weeks
* History of intestinal surgery
* History of severe liver and kidney disease
* History of cardiovascular and cerebrovascular diseases
* History of neuropsychiatric diseases
* Pregnant women or lactating women
* Allergic to any ingredients of the live bacteria tablet
Tele-yoga Program in COPD and Heart Failure

The combined diagnosis of chronic obstructive pulmonary disease (COPD) and heart failure (HF) is common but often missed because of similarities in clinical presentation, risk factors, and patient characteristics. The concurrent presence of both diseases worsens the limitations in exercise capacity and quality of life that patients experience with either disease alone. This pilot study will test the feasibility of a yoga program conducted in patients' homes using multi-point interactive videoconferencing ("Tele- Yoga") for patients with combined COPD/HF diagnoses. The investigators hypothesize that patients who receive a yoga program at home, compared to an educational control group, will experience fewer physical symptoms and better quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Patients with heart failure (HF) who also have COPD according to University of California San Francisco medical record documentation and would like to participate in a home yoga intervention and hospitalization within the past 24 months.
* Patients must: receive permission from their provider to participate in the study
* English-speaking
* Score of 3 on the Mini-Cog test
* Be between the ages of 40 and 85 years
* New York Heart Association Class I-III left ventricular systolic or diastolic HF
* Have moderate-severe COPD defined as post bronchodilator Forced Expiratory Volume (FEV1) in 1 sec \< 80% predicted, FEV1/Forced Vital Capacity ratio \< 70% and history of smoking
* TV, broadband internet connection, enough space to practice yoga in front of the TV, and willing to have research assistant install videoconferencing equipment.

Exclusion Criteria:

* Patients with a history of medication non-compliance as described by their provider
* Hospitalization within the last 3 months
* Myocardial infarction or recurrent angina within the last 6 months
* Severe stenotic valvular disease
* History of sudden cardiac death without subsequent automatic internal defibrillator placement
* Cognitive impairment
* Neuromuscular, orthopedic, or psychiatric illness that would interfere with yoga training
* Oxygen saturation \<85% on 6 liters of nasal oxygen.
PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.


Eligibility Criteria:
Inclusion Criteria:

* Metastatic hormone refractory prostate cancer progressing after docetaxel based therapy
* Adequate bone marrow, liver and kidney function

Exclusion Criteria:

* More than one prior chemotherapy line
* Uncontrolled hypertension
* Brain or leptomeningeal disease
* Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months
A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men

The purpose of this project is to test the efficacy of an HIV prevention behavioral intervention to reduce sexual risk among African-American men who have sex with men (MSM).


Eligibility Criteria:
Inclusion Criteria: identify as African-American, Black, Caribbean Black or multiethnic Black, report sex with men

Exclusion Criteria:

* Participated in pilot
* Identify as transgender
* Plan to move before end of study
* Refuse HIV testing at baseline or identified as a newly diagnosed HIV through testing at the baseline
* Under 18 years of age
Compare the Hemostatic Effectiveness of Chitosan Gauze With Traditional Gauze on Open Wound on 10 Participants.

This study recruited 10 subject participants to compare the hemostasis gauze made by chitosan with traditional cotton gauze to see which one is better in bleeding time, bleeding volume, wound infection and wound healing speed when it is used in open wound treatment.

open wound bleeding and infection care policy development is focusing on efficiency to strengthen internal bleeding, pain, avoidance of infection and promoting wound healing wound. With the changes in the social environment, people caring for hemostasis and wound healing have become increasingly demanding. Presently, studies generally aim to stop the bleeding using trauma care technology and functional capabilities combined with each other as well as inhibit lower infection and can also help assist healing wounds care strategy for the protection of human lives. Therefore, the goal of the plan is to establish new care strategies on open wounds infection to stop the bleeding and to improve the health and safety of the people. The researchers will choose the general biological hemostatic gauze to conduct clinical trials comparing the clinical hemostasis focusing on bleeding time, wound infection in the wound and the wound bacteria penetrating situations in the hope to build a better strategy in rapid hemostasis and wound infection care strategy.

Eligibility Criteria:
Inclusion Criteria:

* Patients need laparotomy, with the expected wound size bigger than 5 cm in length and 2 cm in width.

Exclusion Criteria:

* Have history of allergy to shrimp, crab and other chitins.
* Patients with blood clotting disorders
* Vulnerable group
* Patients with unstable vital sign
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

The primary objective of this program is to provide DCV for 24 weeks to be given in combination with SOF to subjects with chronic hepatitis C with decompensated cirrhosis or post-liver transplant subjects with chronic hepatitis C recurrence with either advanced fibrosis or fibrosing cholestatic hepatitis and who have a serious or immediately life-threatening condition or experienced an event that has decreased their life expectancy to \<12 months, therefore, no research hypothesis will be tested and no specific endpoints are defined. However, safety data will be collected throughout the study as well as efficacy data


Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* Patients chronically infected with Hepatitis C
* Subjects who received a liver transplant, have chronic hepatitis C virus (HCV) recurrence and advanced fibrosis (Metavir F3-F4) or fibrosing cholestatic hepatitis
* Subjects with decompensated cirrhosis defined by Child-Pugh Class C

Exclusion Criteria:

* Patients who are \<18 years old
* Clinical or pathologic evidence of acute ongoing liver graft rejection
* Creatinine clearance (CrCl) ≤30 mL/min (as estimated by Cockcroft and Gault formula)
* Patients who have contraindications to either Daclatasvir (DCV) or Sofosbuvir (SOF)
* Patients who are pregnant or Women of Child Bearing Potential who are not using required contraception
Removal of Lung Nodules After Being Marked With a Microcoil

The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.

The addition of real-time CT imaging and insertion of platinum microcoil markers to the technique of video assisted thoracoscopic stapled resection of subcentimetre pulmonary nodules, will decrease the rate of open thoracotomies required to completely resect the nodules.

Lung cancer is the most common cause of cancer death for both men and women in the industrialized world. Small cell lung cancer accounts for about 25% of lung cancers and is usually widespread when it first presents. The remaining 75% of lung cancers are collectively termed non-small cell lung cancers. When presentation is by symptoms or incidental discovery, about 50 to 60% of non-small cell lung cancers are parenchymal nodules or masses and 40 to 50% are bronchial or hilar. More than 50% of patients with non-small cell cancer will have distant metastases at the time of diagnosis and only 25% will be potentially resectable for cure.1 Overall survival at five years for lung cancer is approximately 15% and has not significantly improved over the last several decades. Prognosis for lung cancer is affected by many factors but one of the most important is the stage of the disease at presentation. Individuals with peripheral lesions less than 3 cm in diameter (T1) at presentation are ideal candidates for surgical resection and have the best outcomes, with 5-year survival rates as high as 60 to 80%.2 Patients with small subcentimeter pulmonary nodes may have even better survival with resection. Computed tomography can now detect cancers less than 4 mm in diameter, and it has been shown that resection of subcentimetre lung cancers results in a survival rate of up to 85%.3 However, Suzuki et al found 54% of 92 patients undergoing video assisted thoracoscopic excision of subcentimetre nodules, required conversion to a thoracotomy. Forty percent of those nodules were found to be malignant.4 The most common reason for this conversion was failure to localize the nodule using thoracoscopic visualization or palpation. Furthermore, univariate and multivariate analysis of eleven variables revealed that if the distance from the pleural surface was greater than 5 mm, the probability of failure to detect the nodule was 63%.

Eligibility Criteria:
Inclusion Criteria:

* subcentimetre lung nodule

Exclusion Criteria:
Zenith Thoracic Alpha (ZTA) Post-Market Data Collection

This study aims to gather real-world clinical data demonstrating the continued safety and performance of the a marketed stent graft (Zenith® Alpha Thoracic Endovascular Graft \[ZTA\]) and collect longer term follow-up to better understand clinical outcomes associated with the expected lifetime of the device.

Per local regulations, this study includes both retrospective and prospective patients. Patients can be included retrospectively if they are treated with the study device from 01 January 2019 until the study site is eligible for prospective enrollment.

Eligibility Criteria:
Inclusion Criteria:

* Patient has been treated/was intended to be treated with ZTA according to the clinical practice from Jan 2019 until site initiation
* The patient is willing to participate in the study and provide written informed consent for study participation or express non-objection or give written consent per local requirements prior to data collection of any data from medical records.

Exclusion Criteria:

* A patient treated with a custom-made fenestrated and/or branched endovascular graft in conjunction with ZTA either during the same procedure or in a staged procedure.
* A patient whose follow-up data collection is not possible (e.g. due to living abroad).
Tokushima Night Guard for Recurrent Aphthous Stomatitis

The investigators will investigate whether the night guard can suppress the development of recurrent aphthous stomatitis (RAS). The investigators will record the patients' oral condition for 60 days before and after intervention with the night guard made of Ethylene-Vinyl Acetate copolymer (EVA). The patients' saliva will be analyzed for measurement of inflammatory cytokines or oxidative stress.

The study involved 20 patients (8 male and 12 female) with RAS. These patients suffered from RAS at least once a month. The investigators will record their oral condition for 60 days before and after intervention with the night guard made of EVA. Their saliva will be analyzed for further studies including measurement of inflammatory cytokines or oxidative stress.

Eligibility Criteria:
Inclusion Criteria:

* Patients suffered from recurrent aphthous stomatitis at least once a month

Exclusion Criteria:

* People do not have a experience of recurrent aphthous stomatitis
Behavior Brain Responses

To compare responses to acute oral doses of ethanol in healthy young adults who experience mainly stimulant subjective effects from the drug or mainly sedative effects.


Eligibility Criteria:
* 21-35 years old
* 4-30 alcoholic drinks per week (as reported on PHQ or TLFB)
* No 'flushing' reaction to alcohol
* BMI 19-26
* High school education or greater, fluent in English
* No night shift work
* No current or past year Axis I psychiatric disorder including drug/alcohol dependence
* No current psychopharmacological treatment
* No lifetime ADHD or prescription for ADHD medication
* No abnormal EKG, cardiovascular illness, high blood pressure
* No medical condition or pharmacological treatment for which alcohol is contraindicated
* Not pregnant, lactating, or planning to become pregnant
* Smoke \<6 cigarettes per day
Metagenomic Analysis of the Link Between Periodontitis and Smoking: Case-control Study

Periodontitis is a widely prevalent disease worldwide that has serious public health consequences. Its prognosis includes tooth loss and edentulism, a condition that negatively affects chewing causing functional disability; and esthetics causing social impairment. Consequently, periodontitis may end up causing marked impairment of the quality of life of the affected patients, impairment of general health and increasing the dental care costs significantly.

Dysbiotic changes in the oral microbiome arise after some microbial species are enriched by primary products resulting from tissue breakdown due to gingivitis. It then triggers the host cells to produce proteinases that mediate loss of marginal periodontal ligaments, apical migration of the junctional epithelium and apical spread of bacterial biofilm.

However, the dysbiotic changes may be more likely to occur in some patients rather than others due to certain risk factors including smoking and immuneinflammatory responses. Thus, the severity of periodontal disease in these patients would be higher. Tobacco smoking is no longer considered to be a habit, but a dependence to nicotine and a chronic relapsing medical disorder. Among its detrimental effects on general health, tobacco smoking increases the risk of periodontitis by 2 to 5 folds. This takes place by increasing the dysbiotic changes in the oral microbiome and so, increasing the severity and extent of the periodontal disease at a younger age. Therefore, smoking has been considered as a modifying factor of periodontitis that should be considered upon periodontitis case grading definition.

Therefore, this research aims to identify the difference in dysbiosis between the three categories of periodontitis, trying to understand the cause of the resistance of each category to treatment compared to the milder category.


Eligibility Criteria:
Inclusion Criteria:

* Patients 18 years or older.
* Patients with periodontitis.
* Probing pocket depth ≥ 4 mm.
* Teeth with CAL≥ 3 mm at ≥2 non-adjacent teeth.
* Clinical indication and/or patient request for treatment of the periodontal condition.

Exclusion Criteria:

* Patients with any systemic diseases.
* Pregnant females.
* Patients who took any antibiotic in the past month.
* Handicapped and mentally retarded patients.
* Patients undergoing radiotherapy.